Pharmacokinetic comparison of sitagliptin and metformin HCl extended-release tablets versus JANUMET® XR in healthy volunteers under fasting and fed conditions

Linling Que, Qin Wei, Yunfei Shi, Ying Ding, Kai Huang, Zhenzhong Qian, Bingjie Huang, Peipei Zhou, Qing HeFrontiers in Pharmacology 2023 · DOI

Abstract

Background and Objectives: Janumet® XR is a fixed-dose combination of sitagliptin and extended-release metformin hydrochloride. While effective, its high cost limits accessibility. This study compared the bioequivalence (BE) of a generic version produced by Nanjing Chia-Tai Tianqing Pharmaceutical Company to the branded Janumet® XR in healthy Chinese subjects.

Methods: Two separate studies (fasting and fed) were conducted using an open, randomized, two-period crossover design with 28 subjects each. Plasma concentrations were measured up to 72 h post-dose to calculate $C_{max}$ and $AUC$.

Results: In both fasting and fed states, the 90% CIs for $C_{max}$, $AUC_{0-t}$, and $AUC_{0-\infty}$ for both sitagliptin and metformin were within the 80.00%–125.00% acceptance limits.

Conclusion: The generic formulation is bioequivalent to Janumet® XR and was well tolerated, offering a potentially more affordable treatment option for diabetes.

Introduction

Managing Type 2 Diabetes Mellitus (T2DM) often requires a multi-drug regimen to achieve glycemic control. JANUMET® XR simplifies treatment by combining sitagliptin (a DPP-4 inhibitor) and metformin (a biguanide) into a single, once-daily extended-release tablet. Despite its clinical benefits, the high cost of brand-name medications often leads to reduced patient adherence. To introduce a more affordable generic version, manufacturers must demonstrate bioequivalence (BE), ensuring the generic "Test" drug performs identically to the "Reference" drug in the human body.

Methods

The researchers conducted two separate studies (fasting and fed) using an open-label, randomized, two-period crossover design. 56 healthy Chinese volunteers (28 per study) were enrolled based on specific inclusion criteria, including age 18+ and a BMI between 19–26 $kg/m^2$.

Study design flowchart

As shown in the study design (Figure 1), subjects were randomized to receive either the Test (T) or Reference (R) drug on Day 1, followed by a 7-day washout period before crossing over to the alternate treatment on Day 8. Blood samples were collected at 19 time points over 72 hours. Plasma concentrations were determined using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Bioequivalence was confirmed if the 90% Confidence Interval (CI) of the T/R ratio for $C_{max}$ and $AUC$ fell between 80.00% and 125.00%.

Results

The generic drug successfully met all regulatory bioequivalence criteria in both physiological states:

  • Fasting Study: Geometric mean ratios (T/R) for sitagliptin $C_{max}$ and $AUC_{0-t}$ were 109.42% and 101.93%, respectively. For metformin, they were 98.69% and 94.12%.
  • Fed Study: Ratios for sitagliptin $C_{max}$ and $AUC_{0-t}$ were 98.41% and 100.30%. For metformin, they were 97.79% and 99.28%.

All 90% CIs for these parameters were strictly within the 80.00%–125.00% range. Both treatments were well-tolerated, with only mild, expected adverse events such as transient hypoglycemia in fasting subjects, which was managed with standard safety protocols including 20% glucose solutions.

Discussion

The study highlights the technical success of mimicking the complex formulation of JANUMET® XR, which features an extended-release metformin core with a sitagliptin coating. Furthermore, it demonstrated that while food intake alters the absolute pharmacokinetics of these drugs—increasing sitagliptin $C_{max}$ while decreasing metformin $C_{max}$—the generic and brand-name formulations remain bioequivalent relative to each other under both conditions.

Conclusion

This study provides the first demonstration that the generic sitagliptin/metformin HCl extended-release tablets produced by Nanjing Chia-Tai Tianqing Pharmaceutical Company are bioequivalent to the branded JANUMET® XR. These findings support the use of this generic formulation as a safe, effective, and more affordable alternative for the management of Type 2 Diabetes.

Summary updated

Abstract

<b>Background and Objectives:</b> Janumet<sup>®</sup> XR is the combination of sitagliptin and extended metformin hydrochloride produced by Merck Sharp & Dohme. It is specially designed for diabetes mellitus patients taking both drugs already. Janumet<sup>®</sup> XR exhibited clinically significant blood glucose lowering efficacy and long-term use safety. However, no generic form of Janumet<sup>®</sup> XR has been approved in western countries. The relatively high cost made the medication less prescribed. A more affordable form of this drug may benefit an immense diabetes mellitus population. The current study compared the bioequivalence (BE) of sitagliptin 100 mg and metformin 1000 mg produced by Nanjing Chia-Tai Tianqing Pharmaceutical Company to Janumet<sup>®</sup> XR in healthy Chinese subjects. <b>Methods:</b> Twenty-eight healthy Chinese subjects were enrolled in Study 1 and 2, respectively. Both studies were conducted with an open, randomized, two-period crossover design using the test (T) or the reference (R) drug. Study 1 is conducted under the fasting state, and Study 2 is under the fed state. Subjects received an oral dose of sitagliptin 100 mg and metformin 1000 mg, and plasma concentrations of sitagliptin and metformin were determined up to 72 h post-dose. Pharmacokinetic (PK) parameters, including maximum serum concentration (C<sub>max</sub>) and area under the concentration-time curve up to the last quantifiable concentration (AUC<sub>0-t</sub>) of both sitagliptin and metformin, were calculated and compared between the T and R treatments. <b>Results:</b> In the fasting study, the geometric mean ratios of C<sub>max</sub>, AUC<sub>0-t</sub>, and AUC<sub>0-∞</sub> for sitagliptin were 109.42%, 101.93%, and 101.95%, respectively; the corresponding ratios for metformin were 98.69%, 94.12%, and 93.42%, respectively. In the fed study, the geometric mean ratios of C<sub>max</sub>, AUC<sub>0-t</sub>, and AUC<sub>0-∞</sub> for sitagliptin were 98.41%, 100.30%, and 100.24%, respectively; the corresponding ratios for metformin were 97.79%, 99.28%, and 100.69%, respectively. The 90% CIs of C<sub>max</sub>, AUC<sub>0-t</sub>, and AUC<sub>0-∞</sub> in both studies were all within acceptance limits (80.00%-125.00%). <b>Conclusion</b>: The results demonstrated for the first time that sitagliptin 100 mg and metformin 1000 mg produced by Nanjing Chia-Tai Tianqing Pharmaceutical Company was bioequivalent to the branded Janumet<sup>®</sup> XR, and both drugs were well tolerated.
BibTeX
@inproceedings{que2023pharmacokinetic,
  author = {Linling Que and Qin Wei and Yunfei Shi and Ying Ding and Kai Huang and Zhenzhong Qian and Bingjie Huang and Peipei Zhou and Qing He},
  title = {{Pharmacokinetic comparison of sitagliptin and metformin HCl extended-release tablets versus JANUMET® XR in healthy volunteers under fasting and fed conditions}},
  booktitle = {Frontiers in Pharmacology},
  year = {2023},
  doi = {10.3389/fphar.2023.1105767},
}
Figure